Gastrointestinal Cancer News

Limited access to health care, misunderstanding of symptoms and certain beliefs about illness are among the key barriers to early diagnosis and treatment of colorectal cancer in patients with lower socioeconomic status, especially those in minority groups, according to new research published in Diseases of the Colon & Rectum.

Recently published data showed no association between direct-acting antiviral therapy and an increased risk for hepatocellular carcinoma recurrence among liver transplantation candidates with hepatitis C who experienced initial complete response to local-regional therapy.

Increased physical activity tracked with a Fitbit during inpatient recovery predicted lower risk for 30- and 60-day hospital readmission after surgery for metastatic peritoneal cancer, according to results of an observational cohort study published in Annals of Behavioral Medicine.

Patients receiving care through the Veterans Affairs health system who underwent a colonoscopy were 61% less likely to die of colorectal cancer, according to research published in Annals of Internal Medicine.

A digital health intervention including an iPad app that educated patients on colorectal cancer screening options and allowed them to order their preferred test increased screening rates by twofold, according to a study published in Annals of Internal Medicine.

Higher concentration of vitamin D correlated significantly with a lower risk for overall cancer and liver cancer, according to recently published data.

The socioeconomic status of patients with anal cancer may influence their survival rates, according to new research published in Cancer.

NEW YORK — Pembrolizumab and nivolumab demonstrated considerable activity in patients with tumors with high levels of microsatellite instability or mutation load, according to a presenter at HemOnc Today New York.

Boston Scientific announced that it has acquired EMcision, a company based in the United Kingdom and Canada.

A blood test called Nu.Q detected 80% of stage 1 colorectal cancers and 66% of precancerous polyps in an asymptomatic screening study in Denmark, according to interim results reported by the developer, VolitionRx.